Summit Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Summit Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2019 to Q3 2024.
  • Summit Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $19.4M, a 2648% increase year-over-year.
  • Summit Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $48.7M, a 508% increase year-over-year.
  • Summit Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $14.1M, a 18.1% increase from 2022.
  • Summit Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11.9M, a 6.69% decline from 2021.
  • Summit Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $12.8M, a 625% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $48.7M $19.4M +$18.7M +2648% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 $30.1M $11.1M +$9.21M +491% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $20.8M $9.51M +$6.73M +243% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $14.1M $8.75M +$6.1M +229% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $8.01M $705K -$2.09M -74.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 $10.1M $1.88M -$621K -24.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $10.7M $2.78M -$1.22M -30.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $11.9M $2.66M -$2.96M -52.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $14.9M $2.8M +$154K +5.83% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $14.8M $2.5M -$1.18M -32% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $15.9M $4M +$3.13M +360% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $12.8M $5.62M +$5.04M +872% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $7.76M $2.64M +$2.28M +632% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $5.48M $3.67M +$3.14M +593% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $2.34M $869K +$572K +193% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 $1.77M $578K Oct 1, 2020 Dec 31, 2020 10-K/A 2022-12-21
Q3 2020 $361K +$117K +48% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $530K +$266K +101% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $297K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q3 2019 $244K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $264K Apr 1, 2019 Jun 30, 2019 8-K 2020-09-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.